Abstract
The children with HIV early antiretroviral (CHER) trial, which began participant enrolment in 2005, released interim results in 2008 showing that early antiretroviral therapy (ART) in HIV-infected infants aged 6–12 weeks reduced all-cause mortality by 76% and HIV disease progression by 75%.1 These results prompted WHO to change their recommendations from initiation of ART in infants at a particular CD4 threshold to universal ART, irrespective of the immunological or clinical stage of disease.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
